Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Nov 21, 2022 3:40pm
127 Views
Post# 35116586

RE:RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

RE:RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stockNonsense ....An acquisition of ONCY would have the agreement with Adlai Nortye become" Null and Void" . Nothing in the agreement as written provides for the transfer of any rights to Adlai Nortye in the event of ONCY's acquisition. And the agreement does not survive into perpetuity, no matter what you think.

Furthermore, Clause 15 of the agreement outlines termination and fails to make any reference to a plausible acquisition of the "Licensor" aka ONCY by a "third party". So by virtue of this omission the agreement becomes "Null and Void" upon a takeover of ONCY.  And by the absence of such a provision Adlai Nortye and the "New CO" will have to seek to renegotiate a new agreement     ...So goodbye to you. 
<< Previous
Bullboard Posts
Next >>